The latest price target for Eagle Pharmaceuticals (OTCEM:EGRX) was reported by Piper Sandler on August 9, 2023. The analyst firm set a price target for $17.00 expecting EGRX to rise to within 12 months (a possible 1906.61% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Eagle Pharmaceuticals (OTCEM:EGRX) was provided by Piper Sandler, and Eagle Pharmaceuticals downgraded their underweight rating.

There is no last upgrade for Eagle Pharmaceuticals

The last downgrade for Eagle Pharmaceuticals Inc happened on August 9, 2023 when Piper Sandler changed their price target from $26 to $17 for Eagle Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eagle Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eagle Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.

While ratings are subjective and will change, the latest Eagle Pharmaceuticals (EGRX) rating was a downgraded with a price target of $26.00 to $17.00. The current price Eagle Pharmaceuticals (EGRX) is trading at is $0.85, which is out of the analyst’s predicted range.